Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma

Cancer

Volumn 86, Issue 11, 1999, Pages 2259-2265

  Camp, Robert L ^a   Rimm, Eric B ^b   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Breast carcinoma; c met; Hepatocyte growth factor scatter factor receptor; Immunohistochemistry; Metastasis; Prognosis

Indexed keywords

SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR MARKERS, BIOLOGICAL;

EID: 0033404948     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2     Document Type: Article

References (37)

1. Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 4) - discriminants for 15-year survival. Cancer 1993;71:2141-50.
2. Fisher ER, Redmond C, Fisher B, Bass G. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP) - prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients. Cancer 1990;65:2121-8.
3. McGuire WL, Tandon AK, Allred C, Chamness GC, Clard GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-15.
4. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 1983;43:2985-90.
5. Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 1985;56:1696-700.
6. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou IY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in nodenegative breast carcinomas. J Clin Oncol 1997;15:2894-904.
7. Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 1993;87:682-4.
8. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
9. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96.
10. Pisters LL, Troncoso P, Zhau HE, Li W, von FA Chung LW. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8.
11. Di Renzo MF, Olivero M, Serini G, Orlandi F, Pilotti S, Belfiore A, et al. Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest 1995;18:134-9.
12. Trovato M, Villari D, Bartolone L, Spinella S, Simone A, Violi MA, et al. Expression of the hepatocyte growth factor and C-Met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 1998;8:125-31.
13. Yonemura Y, Kaji M, Hirono Y, Fushida S, Tsugawa K, Fujimura T, et al. Correlation between overexpression of c-met gene and the progression of gastric cancer. Int J Oncol 1996;8:555-60.
14. Giordano S, Ponzetto C, Di RM, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989;339:155-6.
15. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996;119:591-600.
16. Di Renzo M, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6: 1997-2003.
17. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction (review). J Cell Biol 1994;127:1783-7.
18. Niranjan B, Buluwela L, Yant I, Perusinghe N, Atherton A, Phippard D, et al. HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development 1995;121:2897-908.
19. Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande WG. The met proto-oncogene receptor and lumen formation. Science 1992;257:1258-61.
20. Jin L, Fuchs A, Schnitt SI, Yao Y, Joseph A, Lamszus K, et al. Expression of scatter factor and C-Met receptor in benign and malignant breast tissue. Cancer 1997;79:749-60.
21. Yao Y, Jin L, Fuchs A, Joseph A, Hastings HM, Goldberg ID, et al. Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am J Pathol 1996;149:1707-17.
22. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-3.
23. Yamashita J, Ogawa M, Beppu T. Immunoreactive hepatocyte growth factor is present in tissue extracts from human breast cancer but not in conditioned medium of human breast cancer cell lines. Res Commun Chem Pathol Pharmacol 1993;82:249-52.
24. Wang Y, Selden AC, Morgan N, Stamp GW, Hodgson HJ. Hepatocyte growth factor/scatter factor expression in human mammary epithelium. Am J Pathol 1994;144:675-82.
25. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148:225-32.
26. Tsao MS, Zhu H, Giaid A, Viallet J, Nakamura T, Park M. Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. Cell Growth Dif 1993;4:571-9.
27. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the Met proto-oncogene in papillary renal carcinomas. Nature Genet 1997;16:68-73.
28. Lin JC, Naujokas M, Zhu H, Nolet S, Park M. Intron-exon structure of the Met gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon. Oncogene 1998;16:833-42.
29. Ghoussoub RAD, Dillon DA, D'Aquila T, Rimm EB, Fearon RR, Rimm DL. Expression of C-Met is a strong independent prognostic factor in breast carcinoma. Cancer 1998;82:1513-20.
30. Donegan W. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997;47:28-51.
31. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980;15:239-51.
32. Norton A, Jordan S, Yeomans P. Brief High -Temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed specimens. J Pathol 1994;173:371-9.
33. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Cancer 1991;68:1309-17.
34. Nagy J, Curry GW, Hillan KJ, Mckay IC, Mallon E, Purushotham AD, et al. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 1996;5:15-21.
35. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
36. Black MM, Opler SR, Speer FD. Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes. Surg Gynecol Obstet 1955;100:543-51.
37. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 1995;131:1573-86.